GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study is to collect biological samples from participants with a new diagnosis of cancer (blood and tumor tissue) and from participants who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer participants and to develop models for distinguishing cancer from non-cancer.
This is a prospective, multi-center, observational study with collection of de-identified biospecimens and clinical data from at least 15,000 participants from clinical networks in the United States and Canada. The study will enroll approximately 10,500 cancer participants (CANCER arm) and approximately 4,500 representative participants without a clinical diagnosis of cancer (NON-CANCER arm). Clinical information, demographics, and medical data relevant to cancer status are collected from all participants and their medical record at baseline (time of biospecimen collection), and subsequently from the medical record at intermittent future time points, at least annually for up to 5 years.
Study Type
OBSERVATIONAL
Enrollment
15,254
To collect and study clinically-annotated biospecimens, specifically peripheral blood and contemporary tumor tissue when available, to characterize cfNA profiles from deep sequencing and to estimate the population heterogeneity in two arms of the study.
Time frame: 30 months
To develop and evaluate models for discriminating cancer versus non-cancer and tissue of origin.
Time frame: 30 months
To evaluate concordance of variants identified in sequencing of tumor tissue and cfNA sequencing results in plasma from the same subject.
Time frame: 30 months
To explore the relationship between genomic results and clinical outcomes based on collection of longitudinal information (at least annually for up to 5 years) from medical records for all consenting participants.
Time frame: Year 1, 2, 3, 4, 5
To enable assessment of the performance of an analytically validated clinical laboratory version of the NGS assay (under development) to detect circulating tumor DNA (ctDNA) in plasma.
Time frame: Year 1, 2, 3, 4, 5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Southern Cancer Center, PC - Daphne
Daphne, Alabama, United States
Southern Cancer Center, P.C. - Mobile Infirmary
Mobile, Alabama, United States
Southern Cancer Center, PC - Mobile Airport
Mobile, Alabama, United States
Southern Cancer Center, PC - Springhill Medical Center
Mobile, Alabama, United States
Mayo Clinic - Arizona
Phoenix, Arizona, United States
Mercy Fort Smith
Fort Smith, Arkansas, United States
Sansum Clinic - 540
Santa Barbara, California, United States
Sansum Clinic- 317
Santa Barbara, California, United States
Sansum Clinic - Viborg
Solvang, California, United States
Rocky Mountain Cancer Centers
Aurora, Colorado, United States
...and 130 more locations